Efficacy and safety of the Russian protease inhibitor narlaprevir at treatment-naive and earlier treated noncirrhotic patients with the 1st genotype chronic hepatitis C (PIONEER study)

Efficacy and safety of the Russian protease inhibitor narlaprevir at treatment-naive and earlier treated noncirrhotic patients with the 1st genotype chronic hepatitis C (PIONEER study)

Aim of investigation. To estimate efficacy and safety of narlaprevir (NVR) with ritonavir (RTV), pegilated interferon (peg-IFN) and ribavirin (RBV) at treatmentnaïve and earlier treated noncirrhotic patients with chronic hepatitis C caused by the 1st virus genotype in double blind placebo-controlled...

Full description

Saved in:
Bibliographic Details
Main Authors: M. V. Mayevskaya, V. T. Ivashkin, O. O. Znoyko, Ye. A. Klimova, D. T. Abdurakhmanov, I. G. Bakulin, P. O. Bogomolov, E. Z. Burnevich, M. Yu. Galushko, N. I. Geyvandova, K. V. Zhdanov, Ye. V. Esaulenko, S. N. Kizhlo, D. Yu. Konstantinov, N. I. Mironova, V. G. Morozov, Ye. A. Strebkova, I. G. Nikitin, M. F. Osipenko, V. D. Pasechnikov, O. I. Sagalova, I. M. Khayertynova, V. P. Chulanov, A. A. Yakovlev, I. A. Vasyutin, Ye. P. Tarkhova, E. N. Krasavina, M. Yu. Samsonov
Format: Article
Language:Russian
Published: Gastro LLC 2018-08-01
Series:Российский журнал гастроэнтерологии, гепатологии, колопроктологии
Subjects:
хронический гепатит с
лечение
нарлапревир
Online Access:https://www.gastro-j.ru/jour/article/view/191
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items